BridgeBio Pharma (BBIO) Competitors $23.41 -0.38 (-1.60%) (As of 10/31/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends BBIO vs. BHVN, BPMC, TPTX, PRGO, FOLD, SMMT, GMAB, VTRS, RDY, and SRPTShould you be buying BridgeBio Pharma stock or one of its competitors? The main competitors of BridgeBio Pharma include Biohaven (BHVN), Blueprint Medicines (BPMC), Turning Point Therapeutics (TPTX), Perrigo (PRGO), Amicus Therapeutics (FOLD), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), and Sarepta Therapeutics (SRPT). These companies are all part of the "medical" sector. BridgeBio Pharma vs. Biohaven Blueprint Medicines Turning Point Therapeutics Perrigo Amicus Therapeutics Summit Therapeutics Genmab A/S Viatris Dr. Reddy's Laboratories Sarepta Therapeutics Biohaven (NYSE:BHVN) and BridgeBio Pharma (NASDAQ:BBIO) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations. Does the MarketBeat Community believe in BHVN or BBIO? Biohaven received 231 more outperform votes than BridgeBio Pharma when rated by MarketBeat users. However, 70.43% of users gave BridgeBio Pharma an outperform vote while only 66.72% of users gave Biohaven an outperform vote. CompanyUnderperformOutperformBiohavenOutperform Votes39366.72% Underperform Votes19633.28% BridgeBio PharmaOutperform Votes16270.43% Underperform Votes6829.57% Which has more risk and volatility, BHVN or BBIO? Biohaven has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500. Does the media prefer BHVN or BBIO? In the previous week, BridgeBio Pharma had 4 more articles in the media than Biohaven. MarketBeat recorded 5 mentions for BridgeBio Pharma and 1 mentions for Biohaven. BridgeBio Pharma's average media sentiment score of 0.30 beat Biohaven's score of -0.07 indicating that BridgeBio Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biohaven 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral BridgeBio Pharma 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals hold more shares of BHVN or BBIO? 88.8% of Biohaven shares are owned by institutional investors. Comparatively, 99.8% of BridgeBio Pharma shares are owned by institutional investors. 16.0% of Biohaven shares are owned by insiders. Comparatively, 24.7% of BridgeBio Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has preferable earnings and valuation, BHVN or BBIO? Biohaven has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiohaven$462.51M9.75-$408.17M-$6.83-7.48BridgeBio Pharma$219.12M20.82-$643.20M-$2.63-9.22 Is BHVN or BBIO more profitable? Biohaven has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -207.11%. BridgeBio Pharma's return on equity of 0.00% beat Biohaven's return on equity.Company Net Margins Return on Equity Return on Assets BiohavenN/A -212.83% -157.42% BridgeBio Pharma -207.11%N/A -76.71% Do analysts rate BHVN or BBIO? Biohaven presently has a consensus price target of $61.92, indicating a potential upside of 25.08%. BridgeBio Pharma has a consensus price target of $47.50, indicating a potential upside of 95.80%. Given BridgeBio Pharma's higher possible upside, analysts clearly believe BridgeBio Pharma is more favorable than Biohaven.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biohaven 0 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 3.07BridgeBio Pharma 0 Sell rating(s) 2 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.87 SummaryBridgeBio Pharma beats Biohaven on 10 of the 18 factors compared between the two stocks. Ad Porter & CompanyElection warning coming true… If you missed it, my emergency election broadcast is now available - watch it before it's too late.Click here to watch it now. Get BridgeBio Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BBIO vs. The Competition Export to ExcelMetricBridgeBio PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.56B$7.13B$5.37B$8.41BDividend YieldN/A8.77%5.21%4.20%P/E Ratio-9.2216.48140.7917.72Price / Sales20.82254.251,454.6778.04Price / CashN/A50.1638.9433.56Price / Book-3.145.674.744.59Net Income-$643.20M$151.16M$115.38M$225.45M7 Day Performance0.37%-1.32%-0.54%-0.23%1 Month Performance-4.71%6.33%3.93%1.90%1 Year Performance-6.84%40.64%39.33%33.46% BridgeBio Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BBIOBridgeBio Pharma4.5489 of 5 stars$23.41-1.6%$47.50+102.9%-6.7%$4.40B$219.12M-8.90400Upcoming EarningsBHVNBiohaven2.6998 of 5 stars$50.80-1.8%$61.92+21.9%+82.7%$4.49B$462.51M-5.55239BPMCBlueprint Medicines2.8885 of 5 stars$82.49-0.3%$118.22+43.3%+64.2%$5.17B$362.80M-24.12640Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageTPTXTurning Point TherapeuticsN/A$76.01flatN/A+0.0%$3.81B$30.83M-11.02250PRGOPerrigo4.8781 of 5 stars$26.26+1.9%$37.00+40.9%-6.2%$3.58B$4.43B-28.549,140Upcoming EarningsFOLDAmicus Therapeutics4.4376 of 5 stars$11.39-1.1%$17.13+50.4%+6.0%$3.37B$455.66M-29.21480Upcoming EarningsAnalyst DowngradeSMMTSummit Therapeutics2.8409 of 5 stars$21.42-3.7%$36.00+68.1%+868.8%$15.52B$700,000.00-93.13105Analyst ForecastGMABGenmab A/S4.6695 of 5 stars$23.07-0.3%$45.20+95.9%-20.0%$15.27B$2.39B19.072,204Upcoming EarningsShort Interest ↓Positive NewsHigh Trading VolumeVTRSViatris3.1185 of 5 stars$11.77+0.1%$14.00+18.9%+34.5%$14.05B$15.43B-21.4038,000Upcoming EarningsRDYDr. Reddy's Laboratories1.7217 of 5 stars$75.16-4.2%$87.00+15.8%+14.4%$12.54B$288.51B18.7927,048Upcoming EarningsSRPTSarepta Therapeutics4.9424 of 5 stars$130.30+0.0%$182.95+40.4%+18.7%$12.32B$1.50B289.561,314Upcoming Earnings Related Companies and Tools Related Companies Biohaven Alternatives Blueprint Medicines Alternatives Turning Point Therapeutics Alternatives Perrigo Alternatives Amicus Therapeutics Alternatives Summit Therapeutics Alternatives Genmab A/S Alternatives Viatris Alternatives Dr. Reddy's Laboratories Alternatives Sarepta Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BBIO) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BridgeBio Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BridgeBio Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.